Cargando…

Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8(+)T cells in hepatocellular carcinoma using multiplex quantitative analysis

BACKGROUND: Fibrinogen-like protein 1 (FGL1)—Lymphocyte activating gene 3 (LAG-3) pathway is a promising immunotherapeutic target and has synergistic effect with programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1). However, the prognostic significance of FGL1-LAG-3 pathway and the correlatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Mengzhou, Yuan, Feifei, Qi, Feng, Sun, Jialei, Rao, Qianwen, Zhao, Zhiying, Huang, Peixin, Fang, Tingting, Yang, Biwei, Xia, Jinglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409704/ https://www.ncbi.nlm.nih.gov/pubmed/32762721 http://dx.doi.org/10.1186/s12967-020-02469-8

Ejemplares similares

Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization
por: Guo, Mengzhou, et al.
Publicado: (2021)

Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
por: Shi, An-Ping, et al.
Publicado: (2022)

Abnormal Expression of the LAG-3/FGL-1 Signaling Pathway in Patients with Early-Onset Preeclampsia
por: Liang, Yue, et al.
Publicado: (2022)

FGL1-LAG3 axis impairs IL-10-Producing regulatory T cells associated with Systemic lupus erythematosus disease activity
por: Chen, Kang, et al.
Publicado: (2023)

Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti‐Lag‐3 via reducing FGL1 expression
por: Wang, Jianchu, et al.
Publicado: (2020)

Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma
por: Qi, Feng, et al.
Publicado: (2020)

Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1–FGL1–MYH9 axis
por: Tang, Xi-Yang, et al.
Publicado: (2022)

MT4‐MMP in tumor‐associated macrophages is linked to hepatocellular carcinoma aggressiveness and recurrence
por: Qi, Feng, et al.
Publicado: (2020)

Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape via PD-L1 in Hepatocellular Carcinoma
por: Qi, Feng, et al.
Publicado: (2021)

Engineered Small Extracellular Vesicles as a FGL1/PD‐L1 Dual‐Targeting Delivery System for Alleviating Immune Rejection
por: Tsai, Hsiang‐i, et al.
Publicado: (2021)

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
por: Qian, Wenjing, et al.
Publicado: (2021)

PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics
por: Abdullahi Sidi, Fatima, et al.
Publicado: (2020)

Fgl2: link between hepatitis B and SARS?
por: Robertson, Morag
Publicado: (2003)

Targeting FGL2 in glioma immunosuppression and malignant progression
por: Ma, Xiaoyu, et al.
Publicado: (2022)

Roles of CXCL5 on migration and invasion of liver cancer cells
por: Xu, Xiaojing, et al.
Publicado: (2014)

Does chronic jet lag increase risk of cancer?
por: Khan, Suliman, et al.
Publicado: (2021)

The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer
por: Li, Jia-Jun, et al.
Publicado: (2023)

Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma
por: Yan, Qing, et al.
Publicado: (2022)

LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance
por: Wei, Yiming, et al.
Publicado: (2022)

FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
por: Sun, Cuilan, et al.
Publicado: (2020)

FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
por: Lv, Zheng, et al.
Publicado: (2021)

The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection
por: Shalev, Itay, et al.
Publicado: (2010)

Dynamics of Functionally Graded Laminated (FGL) Media—Theoretical Tolerance Modelling
por: Jędrysiak, Jarosław
Publicado: (2023)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway
por: He, Mingyan, et al.
Publicado: (2022)

Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma
por: Jiang, He, et al.
Publicado: (2021)

FGL2 promotes tumor progression in the CNS by suppressing CD103(+) dendritic cell differentiation
por: Yan, Jun, et al.
Publicado: (2019)

sFgl2-Treg Positive Feedback Pathway Protects against Atherosclerosis
por: An, Tianhui, et al.
Publicado: (2023)

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)

The extent of metalloproteinase-mediated LAG3 cleavage limits the efficacy of PD1 blockade
por: Andrews, Lawrence P, et al.
Publicado: (2015)

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2018)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
por: Gestermann, Nicolas, et al.
Publicado: (2020)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma
por: Yuan, Kai, et al.
Publicado: (2020)

FGL-GAN: Global-Local Mask Generative Adversarial Network for Flame Image Composition
por: Qin, Kui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_epelmip6vkceoldtalgsqbvtp1